PulseAugur
EN
LIVE 21:16:48
中文(ZH) 海思科：创新药HSK51155片临床试验申请获受理

Haisco's novel non-opioid painkiller HSK51155 enters clinical trials

By PulseAugur Editorial · [1 sources] ·

Haisco Pharmaceutical Group has received acceptance for its clinical trial application for HSK51155 tablets from China's National Medical Products Administration. This drug is an orally administered small molecule non-opioid innovative analgesic, developed independently by the company. It aims to provide pain relief while minimizing adverse effects and avoiding addiction risks. AI

IMPACT Potential for new pain management options with reduced side effects and addiction risk.

RANK_REASON Clinical trial application acceptance for a novel drug candidate. [lever_c_demoted from research: ic=1 ai=0.4]

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Haisco's novel non-opioid painkiller HSK51155 enters clinical trials

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Tool
Clinical trial application acceptance for a novel drug candidate. [lever_c_demoted from research: ic=1 ai=0.4]
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
paper, product
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Standard
On-topic for AI-industry coverage; kept in the public index.
Story freshness
109 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Hansoh Pharmaceutical: Clinical Trial Application for Innovative Drug HSK51155 Tablets Accepted

    36氪获悉，海思科公告，公司于近日收到国家药监局下发的HSK51155片境内生产药品注册临床试验《受理通知书》。HSK51155是公司自主研发的具有独立知识产权的口服小分子非阿片类创新镇痛药物，有望在满足患者疼痛控制的同时，减少不良反应的发生并且避免成瘾风险。

RELATED TOPICS